The positive effect of liraglutide (0.9 mg) on NAFLD may be attributed to the direct hepatic effect on hepatocyte lipid metabolism not mediated by insulin sensitization. This evidence concerns the gene INS and metabolic dysfunction-associated steatotic liver disease.